Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
BRIDGEWATER, N.J., Nov. 14, 2016 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at the following investor conferences taking place in New York City:
- Will Lewis, president and chief executive officer, will participate in an analyst-led fireside chat on Wednesday, November 16 at 10:15 AM ET at the Stifel Healthcare Conference.
- Mr. Lewis will also participate in an analyst-led fireside chat on Tuesday, November 29 at 7:30 AM ET at the Piper Jaffray Healthcare Conference.
The presentations will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the live webcast.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral inhibitor of dipeptidyl peptidase I with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled prodrug formulation of treprostinil that may offer a differentiated product profile for rare pulmonary disorders. For more information, visit www.insmed.com.
“Insmed” and “ARIKAYCE” are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Insmed Incorporated: Susan Mesco Head of Investor Relations 908-947-4326
